242 related articles for article (PubMed ID: 34645786)
1. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D
Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786
[TBL] [Abstract][Full Text] [Related]
2. Early Restoration of
Jaramillo TC; Xuan Z; Reimers JM; Escamilla CO; Liu S; Powell CM
eNeuro; 2020; 7(3):. PubMed ID: 32327468
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
Poleg S; Golubchik P; Offen D; Weizman A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():90-96. PubMed ID: 30171992
[TBL] [Abstract][Full Text] [Related]
4. Juvenile Shank3b deficient mice present with behavioral phenotype relevant to autism spectrum disorder.
Balaan C; Corley MJ; Eulalio T; Leite-Ahyo K; Pang APS; Fang R; Khadka VS; Maunakea AK; Ward MA
Behav Brain Res; 2019 Jan; 356():137-147. PubMed ID: 30134148
[TBL] [Abstract][Full Text] [Related]
5. Behavioral phenotypes and neurobiological mechanisms in the Shank1 mouse model for autism spectrum disorder: A translational perspective.
Sungur AÖ; Schwarting RKW; Wöhr M
Behav Brain Res; 2018 Oct; 352():46-61. PubMed ID: 28963042
[TBL] [Abstract][Full Text] [Related]
6. The NMDA receptor modulator zelquistinel durably relieves behavioral deficits in three mouse models of autism spectrum disorder.
Fonteneau M; Brugoux A; Jaccaz D; Donello JE; Banerjee P; Le Merrer J; Becker JA
Neuropharmacology; 2024 May; 248():109889. PubMed ID: 38401792
[TBL] [Abstract][Full Text] [Related]
7. Effects of extended-release 7-nitroindazole gel formulation treatment on the behavior of Shank3 mouse model of autism.
Abdel-Haq M; Ojha SK; Hamoudi W; Kumar A; Tripathi MK; Khaliulin I; Domb AJ; Amal H
Nitric Oxide; 2023 Nov; 140-141():41-49. PubMed ID: 37714296
[TBL] [Abstract][Full Text] [Related]
8. Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience.
Mostafavi M; Gaitanis J
Semin Pediatr Neurol; 2020 Oct; 35():100833. PubMed ID: 32892960
[TBL] [Abstract][Full Text] [Related]
9. The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.
Siani-Rose M; McKee R; Cox S; Goldstein B; Abrams D; Taylor M; Kurek I
Cannabis Cannabinoid Res; 2023 Aug; 8(4):642-656. PubMed ID: 35343818
[No Abstract] [Full Text] [Related]
10. Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications.
Delling JP; Boeckers TM
J Neurodev Disord; 2021 Nov; 13(1):55. PubMed ID: 34784886
[TBL] [Abstract][Full Text] [Related]
11. Replicable in vivo physiological and behavioral phenotypes of the
Dhamne SC; Silverman JL; Super CE; Lammers SHT; Hameed MQ; Modi ME; Copping NA; Pride MC; Smith DG; Rotenberg A; Crawley JN; Sahin M
Mol Autism; 2017; 8():26. PubMed ID: 28638591
[TBL] [Abstract][Full Text] [Related]
12. Kami-shoyo-san ameliorates sociability deficits in ovariectomized mice, a putative female model of autism spectrum disorder, via facilitating dopamine D
Guo Q; Ebihara K; Fujiwara H; Toume K; Awale S; Araki R; Yabe T; Dong E; Matsumoto K
J Ethnopharmacol; 2019 May; 236():231-239. PubMed ID: 30862522
[TBL] [Abstract][Full Text] [Related]
13. Major motor and gait deficits with sexual dimorphism in a Shank3 mutant mouse model.
Matas E; Maisterrena A; Thabault M; Balado E; Francheteau M; Balbous A; Galvan L; Jaber M
Mol Autism; 2021 Jan; 12(1):2. PubMed ID: 33468258
[TBL] [Abstract][Full Text] [Related]
14. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature.
Bilge S; Ekici B
J Cannabis Res; 2021 Dec; 3(1):53. PubMed ID: 34911567
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
[No Abstract] [Full Text] [Related]
16. Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A; Cayam Rand D
Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
[TBL] [Abstract][Full Text] [Related]
17. NEXMIF/KIDLIA Knock-out Mouse Demonstrates Autism-Like Behaviors, Memory Deficits, and Impairments in Synapse Formation and Function.
Gilbert J; O'Connor M; Templet S; Moghaddam M; Di Via Ioschpe A; Sinclair A; Zhu LQ; Xu W; Man HY
J Neurosci; 2020 Jan; 40(1):237-254. PubMed ID: 31704787
[TBL] [Abstract][Full Text] [Related]
18. Hyperbaric Oxygen Therapy Alleviates Social Behavior Dysfunction and Neuroinflammation in a Mouse Model for Autism Spectrum Disorders.
Fischer I; Shohat S; Levy G; Bar E; Trangle SS; Efrati S; Barak B
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232395
[TBL] [Abstract][Full Text] [Related]
19. Shank3 deletion in PV neurons is associated with abnormal behaviors and neuronal functions that are rescued by increasing GABAergic signaling.
Pagano J; Landi S; Stefanoni A; Nardi G; Albanesi M; Bauer HF; Pracucci E; Schön M; Ratto GM; Boeckers TM; Sala C; Verpelli C
Mol Autism; 2023 Aug; 14(1):28. PubMed ID: 37528484
[TBL] [Abstract][Full Text] [Related]
20. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders.
Agarwal R; Burke SL; Maddux M
BMC Psychiatry; 2019 Oct; 19(1):328. PubMed ID: 31664964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
